Neoadjuvant HER2+ Articles

Pyrotinib Combo Delays Progression in Heavily Pretreated HER2+ Breast Cancer
Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer.
Rugo Shares Insight on Intriguing SOPHIA Data in HER2+ Breast Cancer
Hope S. Rugo, MD, discusses the findings from the phase III SOPHIA trial and the potential impact of margetuximab on HER2-positive metastatic breast cancer.
Transformative Agents Push Progress in HER2+ Breast Cancer
Tessa Cigler, MD, MPH, discusses the agents that are improving survival for women with early-stage and metastatic HER2-positive breast cancers.
Novel Approaches Make Headway in HER2+ Metastatic Breast Cancer
Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.
Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer
Michel Velez, MD, provides perspective on the clinical experience with neratinib in patients with early-stage HER2-positive breast cancer as well as promising data that may lead to an indication in the metastatic setting. 
Expert Explains Evolution of De-Escalating Therapies in HER2+ Breast Cancer
Keerthi Gogineni, MD, MSHP, discusses several trials in the breast cancer field, specifically looking at de-escalation therapies.
Neratinib Approved in Canada for Early-Stage HER2+ Breast Cancer
Health Canada has approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early-stage, hormone receptor–positive, HER2-overexpressed/amplified breast cancer within 1 year after completing trastuzumab (Herceptin)-based adjuvant therapy.
FDA Approval Sought for Neratinib Combo in HER2+ Breast Cancer
An application has been submitted to the FDA for neratinib for use in combination with capecitabine for the third-line treatment of patients with HER2-positive metastatic breast cancer.
Incorporating Neoadjuvant and Adjuvant Data in Early-Stage HER2+ Breast Cancer
Yee Chung Cheng, MD, discusses the importance of integrating neoadjuvant and adjuvant trial data into practice in order to optimize outcomes for patients with early-stage HER2-positive breast cancer.
Surgery Shows Potential Survival Benefit in Metastatic HER2+ Breast Cancer
Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.
Publication Bottom Border
Border Publication